tbuckley/cabot-search huggingface dataset:
Utilité de la laparoscopie diagnostique en 2004
Authors: I Benelbarhdadi, H El Mahjour, M Benelhamdya, A Essaid
Journal: Endoscopy (2005)

La laparoscopie est l'une des plus anciennes méthodes de diagnostic endoscopique. Elle connaît cependant un déclin depuis le déveleppement des techniques d'imagerie dont l'ultrasonographie et la tomodensitométrie. Le but de cette étude rétrospective est de définir la valeur diagnostique de la laparoscopie dans la pathologie péritonéale, dans l'orientation diagnostique des ascites quand leurs étiologies restaient indéterminées et dans les iléites terminales si des granulations péritonéales étaient présentes orientant vers une tuberculose plutôt qu'une maladie de Crohn.
Neurovascular coupling response is maintained despite exposure to repetitive sub-concussive head trauma over the course of one contact-sport season
Authors: Jonathan D Smirl, Alexander D Wright, Kevin Bouilane, Kelsey Bryk, Michael Jakovac, Paul van Donkelaar
Journal: British Journal of Sports Medicine (2017)

Objective To examine how head-impact exposures affect the elevation in cerebral blood velocity (CBV) in the posterior cerebral artery (PCA) during visual tasks. Design Prospective Cohort. Setting Laboratory. Participants To date: 40 male contact-sport athletes (19.4±1.2 years) and 3 cross-country athletes (20.0±1.0 years) have completed testing (non-contact controls). Intervention Transcranial Doppler ultrasound indexed PCA CBV during visual tasks. Participants closed their eyes (20-seconds), and when prompted, opened them and completed a visual task (40-seconds). Testing occurred prior-to and upon-completion-of the competitive athletic season. Raw traces from each trial were averaged to enhance the signal-to-noise ratio of outcome measurements. Independent variable tested was time (2). Outcome Eyes-closed CBV (cm/s), peak elevation in CBV (cm/s), relative change in CBV (%) and total activation during the first 30 seconds of the task (indexed via area under the curve-AUC). Head-impact exposure was characterised in a subset of contact-sport athletes (n=29) using the xPatch (X2 Biosystems). Main results RM-ANOVA indicated the contact-sport season had no effects on any outcome metrics: Eyes-closed CBV (p=0.181), peak CBV (p=0.117),% CBV elevation (p=0.252) and AUC (p=0.366), despite experiencing cumulative peak linear accelerations of 8147.2±6215.5 g , and cumulative peak rotational accelerations of 34.5×10 6 ± 59.0×10 6 rad/?s 2 . Conclusions The results from this study suggest neurovascular coupling metrics are maintained throughout a contact-sport season. This indicates nutrient delivery is maintained for neurocognitive challenges despite possible impairments in cerebrovasculature’s ability to buffer blood pressure challenges associated elevations in rotational accelerations experienced during a contact-sport season. Competing interests None.
Radiofréquence multipolaire: peut on repousser les limites de la thermodestruction des tumeurs hépatiques? premiers résultats sur des lésions &gt;30mm
Authors: G Goyault, B Vedrenne, C Turnani, JJ Tuech, R Bader, P Claudé, V Tassetti, G Bors, D Sondag
Journal: Endoscopy (2006)

Depuis 1996 la thermoablation par radio fréquence (RF) des tumeurs hépatiques primitives ou secondaires est devenue une méthode de plus en plus utilisée. Sa principale limite est la taille des tumeurs, avec 30% de récidive pour des diamètres ≥ 30mm et 50% pour des diamètres ≥ 40mm.
False-Positive Uptake of Radioiodine in Renal Hamartoma in a Patient With Differentiated Thyroid Cancer
Authors: Guohua Shen, Zhongzhi Qi, Rui Huang, Bin Liu, Anren Kuang
Journal: Clinical Nuclear Medicine (2017)

A 46-year-old woman with a history of papillary thyroid cancer status post total thyroidectomy underwent the second I radioiodine ablation therapy for lung metastases. Posttherapeutic whole-body I planar images showed diffuse uptake in the lungs and intense focal activity in both sides of the upper abdomen. SPECT/CT of the abdomen localized the uptake in the upper pole of the left kidney and the lower pole of the right kidney. The patient received bilateral partial nephrectomy with pathology demonstrating that these 2 renal lesions were renal hamartomas.
Dilatation pneumatique de l'achalasie chez l'enfant:à propos de 37 cas
Authors: A Tebaibia, N Oumnia, M Lahcene, D Boutarene, N Matougui, MA Boudjella, B Touchene
Journal: Endoscopy (2005)

L'approche thérapeutique de l'achalasie chez l'enfant est controversée. La dilatation pneumatique a été peu évaluée dans des séries pédiatriques importantes, en particulier chez le petit enfant.
Long term cardiac outcomes and anthracycline exposure in breast cancer survivors: A retrospective cohort data linkage and competing risks analysis.
Authors: Kelly Rust, Jeremy Walker, Richard Stoker, Sarah Wild, Peter Henriksen, David A. Cameron, Marjory Maclennan, Maighread Simpson, Christina Lilley, Peter Hall
Journal: Journal of Clinical Oncology (2017)

553 Background: Anthracycline chemotherapy is used frequently in adjuvant breast cancer treatment but there is clinical trial evidence of cardiac toxicity. Attempts to quantify this risk in routine care have been limited by follow up time &amp; confounding factors. The aim of this project was to exploit rich Scottish NHS datasets for this purpose. Methods: Patients treated surgically for stage I-III invasive breast cancer between 2000 &amp; 2010 were identified from a local cancer database (Edinburgh Cancer Centre). Outcomes were captured by linkage to the Scottish Morbidity &amp; death Records. Follow-up was until March 2016. The primary outcome was a cardiac event or cardiac death, identified from coding. Analysis used the Latouche approach (estimating cause-specific hazards &amp; sub-distribution hazards) for the primary outcome &amp; the competing risks of death from breast cancer &amp; death from other causes. Results were adjusted for age, deprivation (SIMD), co-morbidity (Charlson), year of diagnosis, side of radiotherapy, cancer stage, grade, ER &amp; HER 2 status. Results: 4080 patients were identified, 1658 received an anthracycline containing regime, 297 received non-anthracycline chemotherapy &amp; 2125 received no chemotherapy. A total of 33946 women years were analysed. During median follow up of 8.2 years there were 448 cardiac events &amp; 559 breast cancer deaths. After adjustments there was no association between anthracycline use &amp; cardiac outcomes (HR 0.9, 95% CI 0.67-1.21). There was an increased risk of breast cancer death (HR 1.66, 95% CI 1.28-2.16).Age &amp; Charlson score were associated with an increased cardiac risk. Stage &amp; grade were statistically associated with breast cancer death. Conclusions: No increased risk of cardiac events was seen in women treated with anthracyclines, they can be safely used in carefully selected patients. This data suggests selection may be over-cautious, a lower threshold for treatment may lead to improved breast cancer outcomes. Rich routine health datasets &amp; appropriate analysis methods make outcomes monitoring feasible in Scotland. Oncologists are skilled at assessing both cardiac risk factors &amp; breast cancer risk.
Maternal BMI and Glycemia Impact the Fetal Metabolome
Authors: William L. Lowe, James R. Bain, Michael Nodzenski, Anna C. Reisetter, Michael J. Muehlbauer, Robert D. Stevens, Olga R. Ilkayeva, Lynn P. Lowe, Boyd E. Metzger, Christopher B. Newgard, Denise M. Scholtens
Journal: Diabetes Care (2017)

We used targeted metabolomics to determine associations of maternal BMI and glucose levels with cord blood metabolites and associations of cord blood metabolites with newborn birth weight and adiposity in mother-offspring dyads.Targeted metabolomic assays were performed on cord blood serum samples from European ancestry, Afro-Caribbean, Thai, and Mexican American newborns (400 from each ancestry group) whose mothers participated in the Hyperglycemia and Adverse Pregnancy Outcome (HAPO) Study and who had anthropometric measurements at birth.Meta-analysis across the four cohorts demonstrated significant correlation of all cord blood metabolites analyzed with maternal fasting levels of the same metabolites at ∼28 weeks' gestation except for triglycerides, asparagine/aspartate, arginine, and the acylcarnitine C14-OH/C12-DC. Meta-analyses also demonstrated that maternal BMI with or without adjustment for maternal glucose was associated with cord blood metabolites including the branched-chain amino acids and their metabolites as well as phenylalanine. One-hour but not fasting glucose was associated with cord blood 3-hydroxybutyrate and its carnitine ester, a medium-chain acylcarnitine, and glycerol. A number of cord blood metabolites were associated with newborn birth weight and sum of skinfolds, including a negative association of triglycerides and positive association of 3-hydroxybutyrate, its carnitine ester, and serine with both newborn outcomes.Maternal BMI and glycemia are associated with different components of the newborn metabolome, consistent with their independent effects on newborn size at birth. Maternal BMI is associated with a newborn metabolic signature characteristic of insulin resistance and risk of type 2 diabetes in adults.
Abstract 18067: Targeting Mitochondrial DNA to Reduce Consequences of Oxidative Stress: Role in the Prevention of the Diabetic Cardiomyopathy
Authors: Giacinta Guarini, Christopher L Kolz, Yuh F Pung, Vahagn A Ohanyan, Liya Yin, Ian N Bratz, Mario Marzilli, William M Chilian
Journal: Circulation (2011)

Mitochondrial dysfunction and increased oxidative stress are hallmarks of diabetic cardiomyopathy, a condition characterized by increased risk of heart failure, independent of coronary atherosclerosis. Mitochondria not only are the major site of energy production, but also generate reactive oxygen species (ROS), and metabolic signals that produce coronary metabolic vasodilation (coupling of flow to metabolism). Accordingly, we hypothesized that elevations in mitochondrial ROS in obesity and diabetes produce oxidative mitochondrial DNA (mtDNA) injury (fragmentation); thus by repairing mtDNA fragmentation, we would restore coronary metabolic dilation. To test this hypothesis, we studied Zucker fatty obese rats (ZOF), lean littermates (ZL), and ZOF in which mtDNA fragmentation was repaired by administration of a cell permeable recombinant protein containing endonucleaseIII and a mitochondrial localization sequence (mt-tat-ENDOIII), which repairs fragmented mtDNA and restores mitochondrial functions. ZOF were treated daily for 3 days (1 µg/g body weight of mt-tat-ENDOIII). ZOF and ZL rats treated with vehicle were positive and negative controls, respectively. The product of mean arterial pressure and heart rate was used as a surrogate of cardiac work (CW). Myocardial blood flow (MBF) was measured by contrast echocardiography under baseline conditions (hexamethonium) and during NE infusion (i.v. norepinephrine, NE) to increase CW. During metabolic stress, ZOF showed coronary insufficiency compared to ZL (P&lt;0.05). Importantly, coronary metabolic dilation in ZOF was restored by the administration of mt-tat-ENDOIII versus ZL (P=NS). We conclude that mitochondrial dysfunction participates to decrease the efficiency of the coronary metabolic regulation in diabetes. By preventing mt-DNA damage, adequate coronary metabolic dilatation can be restored; this could be a therapeutic approach for the prevention of diabetic cardiomyopathy.
A First-Time-in-Human Study of GSK2636771, a Phosphoinositide 3 Kinase Beta-Selective Inhibitor, in Patients with Advanced Solid Tumors
Authors: Joaquin Mateo, Gopinath Ganji, Charlotte Lemech, Howard A. Burris, Sae-Won Han, Karen Swales, Shaun Decordova, M. Phillip DeYoung, Deborah A. Smith, Shanker Kalyana-Sundaram, Jiuhua Wu, Monica Motwani, Rakesh Kumar, Jerry M. Tolson, Sun Young Rha, Hyun Cheol Chung, Joseph P. Eder, Sunil Sharma, Yung-Jue Bang, Jeffrey R. Infante, Li Yan, Johann S. de Bono, Hendrik-Tobias Arkenau
Journal: Clinical Cancer Research (2017)

Background: The PI3K/protein kinase B (AKT) pathway is commonly activated in several tumor types. Selective targeting of p110β could result in successful pathway inhibition while avoiding the on- and off-target effects of pan-PI3K inhibitors. GSK2636771 is a potent, orally bioavailable, adenosine triphosphate-competitive, selective inhibitor of PI3Kβ.Methods: We evaluated the safety, pharmacokinetics, pharmacodynamics and antitumor activity of GSK2636771 to define the recommended phase II dose (RP2D). During the dose-selection and dose-escalation stages (parts 1 and 2), patients with PTEN-deficient advanced solid tumors received escalating doses of GSK2636771 (25-500 mg once daily) using a modified 3+3 design to determine the RP2D; tumor type-specific expansion cohorts (part 3) were implemented to further assess tumor responses at the RP2D.Results: A total of 65 patients were enrolled; dose-limiting toxicities were hypophosphatemia and hypocalcemia. Adverse events included diarrhea (48%), nausea (40%), and vomiting (31%). Single- and repeat-dose exposure increased generally dose proportionally. GSK2636771 400 mg once daily was the RP2D. Phospho/total AKT ratio decreased with GSK2636771 in tumor and surrogate tissue. A castrate-resistant prostate cancer (CRPC) patient harboring PIK3CB amplification had a partial response for over a year; an additional 10 patients derived durable (≥24 weeks) clinical benefit, including two other patients with CRPC with PIK3CB alterations (≥34 weeks). GSK2636771 400 mg once daily orally induced sufficient exposure and target inhibition with a manageable safety profile.Conclusions: Genomic aberrations of PIK3CB may be associated with clinical benefit from GSK2636771. Clin Cancer Res; 23(19); 5981-92. ©2017 AACR.
Abstract 18325: Changes in Cognition and Lipid-lowering Therapy After the Acute Coronary Syndrome: Results From TRACE-CORE
Authors: Brett L Wanamaker, Kristopher J Swiger, Roger S Blumenthal, Jane S Saczynski, David D McManus, Molly E Waring, Catarina I Kiefe, Seth S Martin
Journal: Circulation (2015)

Introduction: Lipid-lowering therapies (LLT) are a key component of treatment in acute coronary syndrome (ACS). Some studies have found an adverse effect of LLTs on cognition yet evidence is inconsistent. We describe 12-month trajectories of cognition among ACS survivors in relation to post-discharge LLT use. Methods: Adult patients (n=2187) hospitalized for ACS in Georgia and Massachusetts enrolled in Transitions, Risks, and Actions in Coronary Events: Center for Outcomes Research and Education (TRACE-CORE) and underwent serial cognitive assessments from index hospitalization through 12 months via the Telephone Interview for Cognitive Status (TICS; range: 0-41; higher scores indicate better cognitive function). The primary outcome was change in TICS and unadjusted between-group comparisons were conducted using the two-sample T-test at 1, 3, 6, and 12 months. A multivariable linear model was constructed to examine the between-group comparison adjusted for baseline demographics, cardiovascular and in-hospital risk factors, and other comorbidities. Results: Participants were 67% male, 80% non-Hispanic white, and aged 61.4±11.3 years. Ninety-two percent were discharged on LLT. At 1 month follow-up (n=1527), patients improved on subsequent cognitive testing regardless of treatment with LLTs; mean TICS improvement was 1.0 for patients on LLT vs. 1.6 for those untreated (p=0.11). In adjusted models, change in TICS did not differ by LLT use (β= -0.41; 95% CI:-1.15, 0.33). Interval changes at 3, 6, and 12 months did not differ by LLT use, with complete follow-up cognitive testing available for 1345 patients (see figure). Conclusions: The prescription of LLT is not associated with the trajectory of cognitive function after hospital discharge for ACS. Despite concerns about the potential cognitive impact of lipid-lowering drugs raised by previous studies, our findings do not support an adverse impact on cognition among ACS patients treated with LLT.
Favourable Outcome of Elderly Patients with Multiple Myeloma Treated with Tandem Melphalan 100 High-Dose Therapy, Autologous Stem Cell Transplantation and Novel Agents - a Single Center Experience
Authors: Judith Neukirchen, Pia Arat, Charlotte Teutloff, Celina Gerrlich, David Lopez y Niedenhoff, Amelie Boquoi, Ingrida Savickaite, Ariane Dienst, Kathrin Nachtkamp, Norbert Gattermann, Thomas Schroeder, Mustafa Kondakci, Guido Kobbe, Rainer Haas, Roland Fenk
Journal: Blood (2016)
Phase II Study of the Combination of Interleukin-2 with Zoledronic Acid As Maintenance Therapy Following Autologous Stem Cell Transplant in Patients with Multiple Myeloma
Authors: Gabriele Buda, Rita Fazzi, Giovanni Carulli, Sara Galimberti, Paola Sammuri, Enrico Orciuolo, Iacopo Petrini, Fabrizio Accardi, Laura Notarfranchi, Nicola Giuliani, Mario Petrini
Journal: Blood (2016)
Recurrence and survival outcomes of triple-negative breast cancer survivors disease-free at 5-years and relationship to low hormone receptor positivity (1-9% versus <1%).
Authors: Sangeetha Meda Reddy, Arup Kumar Sinha, Limin Hsu, Carlos Hernando Barcenas, Vicente Valero
Journal: Journal of Clinical Oncology (2016)

1077 Background: We counsel our triple negative breast cancer (TNBC) patients that recurrence is highest in the first 5 years after diagnosis. There is limited data with extended follow-up on frequency, characteristics, and predictors of late events. Methods: The MD Anderson database was retrospectively queried for stage I-III TNBC survivors disease-free at 5 years. TNBC was defined as estrogen (ER) and progesterone (PR) receptors < 10% and HER-2/neu negative per previous guidelines. We collected demographic, tumor, treatment, and outcome data. Kaplan-Meier method was used to estimate yearly recurrence free survival (RFS), overall survival (OS), and recurrence free interval (RFI) as defined by STEEP criteria. RFI is time to recurrence without including death as an event. Cox proportional hazards model was used to assess effect of low hormone receptor positivity on outcomes. Results: 881 patients were disease free at 5 years from diagnosis with median follow-up of 8.2 years. Table 1 quantifies cumulative probabilities of surviving without event. 22 patients had late recurrences (27.3% local and 72.7% distant). Most common distant recurrence sites were lung (50%), bone (31.8%), distant lymph nodes (36.4%), liver (18.2%), and brain (13.6%). 16 of these patients died, at median time 1.2 years after recurrence. There were 58 total deaths, 29.3% attributed to breast cancer, 13.8% to other, and 56.9% cause unknown. 19 patients developed second primary breast cancers and were censored from further analysis. Low hormone receptor positivity (ER and/or PR 1-9% versus < 1%) conferred higher risk for late events on multivariate analysis (HR 1.95 for RFS, p = 0.03; HR 1.81 for OS, p = 0.12; HR 1.82, p = 0.26 for RFI). Conclusions: 5 year disease-free TNBC survivors have a low probability of recurring over the subsequent 5 years. 10-year RFI was 98%, RFS 91%, and OS 93%. Patients with low hormone receptor cancers were found to have higher risk of late events. Cumulative event-free survival probabilities. Year From Diagnosis RFI RFS OS 5-6 0.99 0.97 0.98 6-7 0.98 0.96 0.98 7-8 0.98 0.94 0.97 8-9 0.98 0.92 0.95 9-10 0.98 0.91 0.93 10-12 0.98 0.90 0.92 12-15 0.95 0.82 0.87
MFN2 might be a risk factor for lung adenocarcinoma.
Authors: Yuqing Lou, Yanwei Zhang, Jianlin Xu, Ping Gu, Wei Zhang, Xueyan Zhang, Hua Zhong, Liyan Jiang, Baohui Han
Journal: Journal of Clinical Oncology (2017)

e13007 Background: Genetic mutations in Mitofusin-2(MFN2) interrupt mitochondrial fusion and cause the untreatable neurodegenerative condition Charcot-Marie-Tooth disease type 2A( Nature, December 2016). MFN2 was initially identified as a hypertension-associated gene and implicated in the pathogenesis of multiple cancer types. However, underlying mechanisms of MFN2 in lung adenocarcinoma was unclear. Methods: MFN2 expression at protein level was examined in 30 pair lung adenocarcinoma/adjacent normal lung samples with immunohistochemistry staining. Then MFN2 knocked down in human lung adenocarcinoma cells A549 with lentiviral-mediated shRNA strategy. The effects of MFN2 knockdown on cell proliferation, cell cycle process, cell migration and invasion was investigated in A549 cells. MFN2-knockdown induced gene expression changes was analyzed by microarray assay and then functional pathway enrichment analysis was performed to identify critical pathways involved in MFN2-mediated lung adenocarcinoma development. The expression changes of downstream factors were determined by western blot. Furthermore, tumor models in nude mice were generated. Tumor formation and progression in these mice were analyzed. Results: As compared to adjacent normal lung tissues, MFN2 expression was significantly higher in lung adenocarcinoma tissues with positive MFN2 signals in 90% (27/30) lung adenocarcinoma tissues and only in 26.7% (8/30) adjacent normal tissues. Furthermore, MFN2 knockdown inhibited cell proliferation, induced cell cycle arrest and blocked invasion behavior in A549 cells. MFN2-knockdown induced gene expression changes in A549 cells was analyzed by microarray assay. Functional pathway enrichment analysis revealed that 6 pathways were enriched in deregulated genes including Cell cycle, DNA replication, ECM-receptor interaction, Focal adhesion, MAPK signaling pathway and Chemokine signaling pathway. Downregulation of RAP1A and upregulation of RALB and ITGA2 identified in MFN2-knockdown cells by microarray analysis were confirmed by western blot. In vivo, tumor formation and progression in nude mice showed that MFN2 knockdown reduced tumorigenesis of A549 cells. Conclusions: MFN2 overexpression run a risk of lung adenocarcinoma.